Business Description
SomnoMed Ltd
ISIN : AU000000SOM1
Total Employee Number:
22Description
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.73 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | 1.17 | |||||
Interest Coverage | 6.99 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.08 | |||||
Beneish M-Score | -2.54 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -8.4 | |||||
3-Year EBITDA Growth Rate | 68.7 | |||||
3-Year EPS without NRI Growth Rate | 27.5 | |||||
3-Year Book Growth Rate | -5.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.44 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.45 | |||||
9-Day RSI | 43.33 | |||||
14-Day RSI | 43.14 | |||||
3-1 Month Momentum % | -1.14 | |||||
6-1 Month Momentum % | -14.36 | |||||
12-1 Month Momentum % | -4.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.76 | |||||
Quick Ratio | 1.46 | |||||
Cash Ratio | 0.73 | |||||
Days Inventory | 55.57 | |||||
Days Sales Outstanding | 46.77 | |||||
Days Payable | 98.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -25.9 | |||||
Shareholder Yield % | -0.93 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 59.81 | |||||
Operating Margin % | 0.91 | |||||
Net Margin % | -2.16 | |||||
EBITDA Margin % | 4.77 | |||||
FCF Margin % | 1.58 | |||||
OCF Margin % | 6.63 | |||||
ROE % | -5.34 | |||||
ROA % | -3.25 | |||||
ROIC % | 2.44 | |||||
3-Year ROIIC % | 317.28 | |||||
ROC (Joel Greenblatt) % | -0.05 | |||||
ROCE % | -0.01 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 14.89 | |||||
PS Ratio | 0.86 | |||||
PB Ratio | 2.06 | |||||
Price-to-Tangible-Book | 3.43 | |||||
Price-to-Free-Cash-Flow | 59.05 | |||||
Price-to-Operating-Cash-Flow | 13.12 | |||||
EV-to-EBIT | -12766.03 | |||||
EV-to-EBITDA | 15.8 | |||||
EV-to-Revenue | 0.75 | |||||
EV-to-Forward-Revenue | 0.79 | |||||
EV-to-FCF | 51.3 | |||||
Price-to-GF-Value | 1.01 | |||||
Price-to-Median-PS-Value | 0.42 | |||||
| Price-to-Net-Current-Asset-Value | 6.85 | |||||
Earnings Yield (Greenblatt) % | -0.01 | |||||
FCF Yield % | 1.85 | |||||
Forward Rate of Return (Yacktman) % | 7.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SomnoMed Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 67.069 | ||
| EPS (TTM) (€) | -0.007 | ||
| Beta | 1.5672 | ||
| 3-Year Sharpe Ratio | 0.08 | ||
| 3-Year Sortino Ratio | 0.13 | ||
| Volatility % | 42.62 | ||
| 14-Day RSI | 43.14 | ||
| 14-Day ATR (€) | 0.022835 | ||
| 20-Day SMA (€) | 0.2925 | ||
| 12-1 Month Momentum % | -4.42 | ||
| 52-Week Range (€) | 0.252 - 0.49 | ||
| Shares Outstanding (Mil) | 219.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SomnoMed Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SomnoMed Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
SomnoMed Ltd Frequently Asked Questions
What is SomnoMed Ltd(STU:RJV)'s stock price today?
The current price of STU:RJV is €0.27. The 52 week high of STU:RJV is €0.49 and 52 week low is €0.25.
When is next earnings date of SomnoMed Ltd(STU:RJV)?
The next earnings date of SomnoMed Ltd(STU:RJV) is .
Does SomnoMed Ltd(STU:RJV) pay dividends? If so, how much?
SomnoMed Ltd(STU:RJV) does not pay dividend.
Press Release
Articles on SomnoMed Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers